Level C· Early human research exploring benefitsProspective StudyPubMed

Human mesenchymal stem cells exhibit altered mitochondrial dynamics and poor survival in high glucose microenvironment.

Abu-El-Rub E., Almahasneh F., Khasawneh RR., Alzu'bi A., Ghorab D., Almazari R.

Prospective Study on Systemic / IV, published in World J Stem Cells (2023) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
World J Stem Cells (2023)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
38179215
DOI
10.4252/wjsc.v15.i12.1093

Abstract (original English)

Mesenchymal stem cells (MSCs) are a type of stem cells that possess relevant regenerative abilities and can be used to treat many chronic diseases. Diabetes mellitus (DM) is a frequently diagnosed chronic disease characterized by hyperglycemia which initiates many multisystem complications in the long-run. DM patients can benefit from MSCs transplantation to curb down the pathological consequences associated with hyperglycemia persistence and restore the function of damaged tissues. MSCs therapeutic outcomes are found to last for short period of time and ultimately these regenerative cells are eradicated and died in DM disease model. To investigate the impact of high glucose or hyperglycemia on the cellular and molecular characteristics of MSCs. Human adipose tissue-derived MSCs (hAD-MSCs) were seeded in low (5.6 mmol/L of glucose) and high glucose (25 mmol/L of glucose) for 7 d. Cytotoxicity, viability, mitochondrial dynamics, and apoptosis were deplored using specific kits. Western blotting was performed to measure the protein expression of phosphatidylinositol 3-kinase (PI3K), TSC1, and mammalian target of rapamycin (mTOR) in these cells. hAD-MSCs cultured in high glucose for 7 d demonstrated marked decrease in their viability, as shown by a significant increase in lactate dehydrogenase ( P < 0.01) and a significant decrease in Trypan blue ( P < 0.05) in these cells compared

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research